Related Experiment Video
Updated: Feb 6, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
A Population-Based Pharmacokinetic Model Approach to Pantoprazole Dosing for Obese Children and Adolescents
Valentina Shakhnovich1,2, P Brian Smith3, Jeffrey T Guptill3
1The Children's Mercy Hospital, Kansas City, MO, USA. vshakhnovich@cmh.edu.
Insights
Obese children have reduced pantoprazole clearance, but current weight-tiered dosing achieves therapeutic exposures. Further research is needed due to significant inter-individual variability in pantoprazole area under the curve.
Area of Science:
- Pharmacology
- Pediatric Gastroenterology
- Pharmacokinetics
Background:
- Obese children are at high risk for acid-related diseases, yet pharmacokinetic data for proton pump inhibitors (PPIs) are limited.
- Previous studies indicated decreased total body weight-adjusted pantoprazole clearance in obese children.
Purpose of the Study:
- To develop a population pharmacokinetic (PopPK) model for pantoprazole in obese children.
- To evaluate pantoprazole dosing strategies for obese pediatric patients using simulation.
Main Methods:
- Utilized pharmacokinetic data from a prospective study of 40 obese children (aged 6-17 years).
- Developed a two-compartment PopPK model using NONMEM, incorporating CYP2C19 genotype and total body weight.
- Evaluated model performance via bootstrapping and predictive checks; simulated exposures for common dosing scenarios.
Main Results:
- The best-fit PopPK model identified CYP2C19 genotype and total body weight as significant covariates.
- Obese children exhibited significantly reduced weight-normalized pantoprazole clearance (CL/F) compared to existing data.
- The FDA-approved weight-tiered dosing strategy achieved therapeutic pantoprazole exposures (AUC0-∞) without over- or under-prediction.
Conclusions:
- Current FDA-approved weight-tiered dosing for pantoprazole is supported for obese children.
- Empiric dose escalation of PPIs in obese children is not recommended based on these findings.
- Significant inter-individual variability (3- to 5-fold) in pantoprazole AUC0-∞ persists with current dosing.
Background And Aims:
Pharmacokinetic data for proton pump inhibitors (PPIs), acid-suppression drugs commonly prescribed to children, are lacking for obese children who are at greatest risk for acid-related disease. In a recent multi-center investigation, we demonstrated decreased, total body weight adjusted, apparent clearance (CL/F) of the PPI pantoprazole for obese children compared with their non-obese peers. Subsequently, we developed a population-based pharmacokinetic (PopPK) model to characterize pantoprazole disposition and evaluated appropriate pantoprazole dosing strategies for obese pediatric patients, using simulation.
Methods:
Pharmacokinetic data from the only prospective study of PPIs in obese children (aged 6-17 years; n = 40) included 273 pantoprazole and 256 pantoprazole-sulfone plasma concentrations, after single oral-dose administration, and were used for pantoprazole model development and covariate analysis (NONMEM®). Model evaluation was performed via bootstrapping and predictive checks, and the final model was applied to simulate systemic pantoprazole exposures for common dosing scenarios.
Results:
A two-compartment PopPK model, which included CYP2C19 genotype and total body weight, provided the best fit. Resultant, typical, weight-normalized pantoprazole parameter estimates were different than previously reported for children or adults, with significantly reduced pantoprazole CL/F for obese children. Of the dosing scenarios evaluated, the weight-tiered approach, approved by the US Food and Drug Administration, achieved pantoprazole exposures [area under the curve (AUC0-∞)] within ranges previously reported as therapeutic, without over- or under-prediction for obese children.
Conclusions:
Our data argue against empiric dose escalation of PPIs for obese children and support current FDA-approved pediatric weight-tiered dosing for pantoprazole; however, 3- to 5-fold inter-individual variability in pantoprazole AUC0-∞ remained using this dosing approach.
More Related Videos
07:15Author Spotlight: Understanding Adolescent Social Adversity Effects on Neurodevelopment in Mice
Published on: March 15, 2024
06:16White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice
Published on: September 9, 2025
Related Concept Videos
Drug Dosing: Obese Patients
Drug Dosing: Infants and Children
Model Approaches for Pharmacokinetic Data: Compartment Models
Two primary types of compartment models are recognized: mammillary and catenary. The more...
Model Approaches for Pharmacokinetic Data: Physiological Models
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Analysis of Population Pharmacokinetic Data